Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
HLN 
Haleon plc (HLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: HLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.93
1 Year Target Price $11.93
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 50.19B USD | Price to earnings Ratio 24.5 | 1Y Target Price 11.93 |
Price to earnings Ratio 24.5 | 1Y Target Price 11.93 | ||
Volume (30-day avg) 5 | Beta 0.22 | 52 Weeks Range 8.71 - 11.35 | Updated Date 02/22/2026 |
52 Weeks Range 8.71 - 11.35 | Updated Date 02/22/2026 | ||
Dividends yield (FY) 0.61% | Basic EPS (TTM) 0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2026-02-25 | When Before Market | Estimate 0.1137 | Actual - |
Profitability
Profit Margin 13.81% | Operating Margin (TTM) 22.21% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9.38% |
Valuation
Trailing PE 24.5 | Forward PE 16.53 | Enterprise Value 60293806261 | Price to Sales(TTM) 4.55 |
Enterprise Value 60293806261 | Price to Sales(TTM) 4.55 | ||
Enterprise Value to Revenue 4.02 | Enterprise Value to EBITDA 16.31 | Shares Outstanding 4453123538 | Shares Floating 8978890200 |
Shares Outstanding 4453123538 | Shares Floating 8978890200 | ||
Percent Insiders 0.11 | Percent Institutions 12.73 |
Upturn AI SWOT
Haleon plc
Company Overview
History and Background
Haleon plc was formed in July 2022 as a demerger from GSK plc, becoming an independent consumer healthcare company. It inherited a portfolio of well-established brands from GSK's former consumer healthcare division. Key milestones include its IPO on the London Stock Exchange and New York Stock Exchange in 2022, marking its debut as a standalone entity focused on health and well-being.
Core Business Areas
- Wellness: This segment focuses on nutritional products and supplements aimed at promoting overall health and well-being, including vitamins and minerals.
- Oral Health: This segment comprises a wide range of products for dental hygiene, including toothpaste, toothbrushes, and mouthwash, designed to prevent and treat oral health issues.
- Pain Relief: This segment offers over-the-counter (OTC) medications for managing everyday pain and discomfort, such as analgesics and anti-inflammatories.
- Respiratory Care: This segment includes products for relieving symptoms associated with respiratory conditions, such as cough, cold, and allergy relief.
- Digestive Health: This segment provides solutions for digestive ailments, including antacids, laxatives, and probiotics.
Leadership and Structure
Haleon plc is led by a Board of Directors, with Brian Gallagher serving as the Chair and Brian McNamara as the CEO. The company operates with a global structure, managing its diverse brand portfolio across various geographic regions. Its organizational structure is designed to support brand-led growth and innovation in the consumer healthcare market.
Top Products and Market Share
Key Offerings
- Description: A leading toothpaste brand specializing in treating tooth sensitivity. Its primary competitors include Colgate (especially Colgate Sensitive Pro-Relief) and Crest (especially Crest Pro-Health Advanced Sensitivity). Haleon aims for significant market share in the sensitive toothpaste segment through continuous product innovation and targeted marketing.
- Market Share Data: Not publicly disclosed at the product level, but Sensodyne is a significant contributor to Haleon's Oral Health segment revenue.
- Product Name 1: Sensodyne
- Description: A widely recognized brand of ibuprofen for pain relief. Key competitors include Bayer's Aleve (naproxen sodium) and generic ibuprofen products. Advil maintains strong brand recognition and loyalty in the pain relief market.
- Market Share Data: Not publicly disclosed at the product level, but Advil is a major brand within Haleon's Pain Relief segment.
- Product Name 2: Advil
- Description: A popular brand of multivitamins and dietary supplements. Competitors include Bayer's One A Day, Nature Made, and store-brand supplements. Centrum's broad range of formulations caters to various age groups and health needs.
- Market Share Data: Not publicly disclosed at the product level, but Centrum is a cornerstone of Haleon's Wellness segment.
- Product Name 3: Centrum
- Description: A line of products designed to relieve cold and flu symptoms. Major competitors include Procter & Gamble's Vicks NyQuil and DayQuil, and various other OTC cold and flu remedies. Theraflu is known for its hot liquid formulations.
- Market Share Data: Not publicly disclosed at the product level, but Theraflu is a key brand in Haleon's Respiratory Care segment.
- Product Name 4: Theraflu
Market Dynamics
Industry Overview
Haleon operates in the global consumer healthcare industry, characterized by strong brand loyalty, a growing demand for preventative health solutions, and an increasing consumer focus on self-care. The market is driven by factors such as an aging population, rising disposable incomes in emerging markets, and a greater awareness of health and wellness. The industry is competitive, with both large multinational corporations and smaller specialized players.
Positioning
Haleon is positioned as a leading global consumer healthcare company with a strong portfolio of trusted, science-backed brands. Its competitive advantages include its extensive brand equity, robust distribution networks, significant R&D capabilities, and a deep understanding of consumer needs. The company benefits from a diversified product offering across multiple health categories, reducing reliance on any single segment.
Total Addressable Market (TAM)
The global consumer healthcare market is estimated to be worth hundreds of billions of dollars and is projected to continue growing. Haleon, with its broad portfolio and global reach, is a significant player within this TAM, aiming to capture a substantial share across its core segments, particularly in Oral Health, Wellness, and Pain Relief.
Upturn SWOT Analysis
Strengths
- Strong portfolio of well-established and trusted brands (e.g., Sensodyne, Advil, Centrum).
- Significant global presence and distribution network.
- Proven track record in consumer marketing and brand building.
- Commitment to science-backed products and innovation.
- Diversified revenue streams across multiple health categories.
Weaknesses
- As a relatively new independent entity, integration and synergy realization from the GSK demerger are ongoing.
- Reliance on certain key brands for a significant portion of revenue.
- Potential for pricing pressures from competitors and private label brands.
- Navigating evolving regulatory landscapes in different markets.
Opportunities
- Growing consumer demand for self-care and preventative health solutions.
- Expansion into emerging markets with increasing disposable incomes.
- Leveraging digital channels for direct-to-consumer engagement and e-commerce growth.
- Strategic acquisitions to expand product portfolio or geographic reach.
- Innovation in new product formulations and delivery systems.
Threats
- Intense competition from established players and new entrants.
- Potential for product recalls or negative publicity affecting brand reputation.
- Economic downturns impacting consumer discretionary spending on health products.
- Changes in healthcare regulations and reimbursement policies.
- Supply chain disruptions and rising input costs.
Competitors and Market Share
Key Competitors
- Procter & Gamble (PG)
- Johnson & Johnson (JNJ)
- Reckitt Benckiser Group plc (RBG)
- Colgate-Palmolive Company (CL)
Competitive Landscape
Haleon faces a highly competitive landscape. Its advantages lie in its specialized focus on consumer healthcare and its deep understanding of consumer needs, supported by strong brand equity. However, competitors like P&G and J&J have vast resources and diversified portfolios that include consumer healthcare. Reckitt Benckiser is also a strong player, particularly in hygiene and health. Colgate-Palmolive is a dominant force in oral care. Haleon must continually innovate and effectively market its brands to maintain and grow its market share.
Growth Trajectory and Initiatives
Historical Growth: Haleon's 'historical growth' as an independent entity is limited to its inception in 2022. Prior to that, its brands were part of GSK's consumer healthcare division, which exhibited consistent growth driven by brand strength and market penetration. Haleon's initial performance post-demerger suggests continued organic growth driven by its established product lines.
Future Projections: Analyst estimates for Haleon's future growth typically focus on a combination of organic growth (driven by innovation, market penetration, and category expansion) and potential inorganic growth through strategic acquisitions. Projections generally anticipate modest to moderate revenue growth, supported by its strong brand portfolio and the expanding global consumer healthcare market.
Recent Initiatives: Continued investment in brand marketing and consumer engagement to drive organic growth.,Focus on product innovation within key categories like Oral Health and Wellness.,Exploring opportunities to leverage digital platforms for enhanced consumer reach and e-commerce sales.,Integration and operational efficiency improvements following the demerger from GSK.
Summary
Haleon plc is a strong, independent consumer healthcare company with a robust portfolio of trusted brands across key health categories. Its strengths lie in brand equity, global reach, and a focus on science-backed products. While facing intense competition and the ongoing integration from its demerger, Haleon has significant opportunities in the growing self-care market and emerging economies. The company needs to continue its focus on innovation and digital engagement to maintain its competitive edge and drive future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Haleon plc Investor Relations
- Company Financial Reports (Annual and Quarterly)
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated and may vary based on reporting methodology and scope. Future projections are subject to market uncertainties and risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haleon plc
Exchange NYSE | Headquaters - | ||
IPO Launch date 2022-07-22 | CEO & Executive Director Mr. Brian James McNamara | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 24561 | Website https://www.haleon.com |
Full time employees 24561 | Website https://www.haleon.com | ||
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.